Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. [electronic resource]
Producer: 20200403Description: e407-e412 p. digitalISSN:- 1938-0690
- Female
- Humans
- Male
- Afatinib -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Squamous Cell -- drug therapy
- ErbB Receptors -- antagonists & inhibitors
- Immunotherapy -- methods
- Lung Neoplasms -- drug therapy
- Mutation -- genetics
- Neoplasm Staging
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Survival Analysis
- Treatment Outcome
- Clinical Trials, Phase II as Topic
No physical items for this record
Publication Type: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.